Passage Bio Inc. (PASG): Price and Financial Metrics
GET POWR RATINGS... FREE!
PASG Stock Price Chart Interactive Chart >
PASG Price/Volume Stats
|Current price||$1.86||52-week high||$16.14|
|Prev. close||$1.76||52-week low||$1.57|
|Day high||$1.88||Avg. volume||379,124|
|50-day MA||$2.49||Dividend yield||N/A|
|200-day MA||$6.26||Market Cap||101.01M|
Passage Bio Inc. (PASG) Company Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Most Popular Stories View All
PASG Latest News Stream
|Loading, please wait...|
PASG Latest Social Stream
View Full PASG Social Stream
Latest PASG News From Around the Web
Below are the latest news stories about Passage BIO Inc that investors may wish to consider to help them evaluate PASG as an investment opportunity.
PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic)
No summary available.
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregivers Interim safety data at three and nine months in Imagine-1 showed low dose PBGM01 well tolerated with no serious adverse events reported and no evidence of dorsal root ganglion toxicity First patients dosed in Cohort 2 (late infantile with high dose PBGM01) and Cohort 3 (early infantile with low dose PBGM01); anticipate reporting initial biomarker and safety data in 2H2022 Management to host conference call and webcast on Friday, February 11 at 1 p.m. ET PHILADELPHIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG ), a clinical-stage genetic medicines company focused on developing transfor...
No summary available.
If you want to know who really controls Passage Bio, Inc. ( NASDAQ:PASG ), then you'll have to look at the makeup of...
PASG Price Returns